CTEV
Claritev Corporation
NYSE · Healthcare · Medical - Healthcare Information Services · US
$38.43
−1.69%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 994.7M | 965.4M | 930.6M | 961.5M | 1.1B |
| Cost of Revenue | 554.3M | 698.8M | 239.4M | 235.5M | 204.1M |
| Gross Profit | 440.3M | 266.6M | 691.2M | 726.1M | 875.6M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 209.3M | 221.5M | 160.2M | 136.0M | 132.1M |
| General & Admin Expense | 209.3M | 221.5M | 160.2M | 136.0M | 132.1M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 182.2M | — | 1.9B | 428.1M | 1.1B |
| Total Operating Expenses | 391.5M | 221.5M | 2.1B | 564.1M | 1.2B |
| Cost and Expenses | 945.8M | 920.4M | 2.3B | 799.5M | 1.4B |
| Operating Income (EBIT) | 48.8M | 45.1M | (1.4B) | 162.0M | (362.7M) |
| Non-Operating | |||||
| Interest Income | 1.1M | 1.6M | 3.1M | 8.2M | 3.5M |
| Interest Expense | 398.8M | 400.1M | 326.4M | 333.2M | 303.4M |
| Net Interest Income | (397.7M) | (398.5M) | (323.2M) | (325.0M) | (299.9M) |
| Other Non-Op Income/Expense | (371.3M) | (418.1M) | (380.8M) | (269.0M) | (198.0M) |
| Non-Operating Income (excl Interest) | (27.5M) | 18.1M | 54.4M | (64.2M) | (105.4M) |
| EBT (Pre-Tax Income) | (322.4M) | (373.1M) | (1.8B) | (107.1M) | (560.7M) |
| Income Tax Expense | (39.3M) | (88.8M) | (124.9M) | (15.4M) | 12.2M |
| Bottom Line | |||||
| Net Income | (283.1M) | (284.3M) | (1.6B) | (91.7M) | (572.9M) |
| Earnings from Cont. Ops | (283.1M) | (284.3M) | (1.6B) | (91.7M) | (572.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (283.1M) | (284.3M) | (1.6B) | (91.7M) | (572.9M) |
| Per Share | |||||
| Basic EPS | ($17.01) | ($17.30) | ($101.92) | ($5.69) | ($35.87) |
| Diluted EPS | ($17.01) | ($17.30) | ($101.92) | ($5.69) | ($35.87) |
| Revenue Per Share | $58.63 | $58.74 | $57.63 | $59.62 | $67.60 |
| Shares | |||||
| Basic Shares Outstanding | 17.0M | 16.4M | 16.1M | 16.1M | 16.0M |
| Diluted Shares Outstanding | 17.0M | 16.4M | 16.1M | 16.1M | 16.0M |
| Profitability Metrics | |||||
| EBITDA | 590.6M | 475.4M | (1.0B) | 651.9M | 158.3M |
| D&A | 514.2M | 448.5M | 436.4M | 425.8M | 415.7M |
| EBIT | 76.4M | 27.0M | (1.4B) | 226.1M | (257.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026